One Free Meal From Industry Ups Brand-Name Rx Among Doctors

This article originally appeared here.
Share this content:
One Free Meal From Industry Ups Brand-Name Rx Among Doctors
One Free Meal From Industry Ups Brand-Name Rx Among Doctors

MONDAY, June 20, 2016 (HealthDay News) -- Physicians who receive even one free meal, valued at less than $20 on average, are more likely to prescribe a promoted brand-name drug than a cheaper generic alternative, compared with doctors who did not accept a meal, according to a study published online June 20 in JAMA Internal Medicine.

University of California, San Francisco, researchers linked information from two federal databases. The team identified the most-prescribed brand-name drugs in each of four common drug classes in 2013. These included Forest Laboratories' Bystolic (nebivolol) and Daiichi Sankyo's Benicar (olmesartan medoxomil), as well as AstraZeneca's Crestor (rosuvastatin calcium) and Pfizer's Pristiq (desvenlafaxine succinate).

The researchers found 279,669 physicians received 63,524 payments totaling $1.4 million related to the four brand-name drugs. Ninety-five percent of payments were for meals, with an average cost of less than $20. Of those doctors, 155,849 wrote more than 20 prescriptions in at least one of the four categories. Even after adjusting for other factors like prescribing volume, doctors who received a single meal were more likely to prescribe Crestor over other statins, Bystolic over other β-blockers, Benicar over other angiotensin-converting enzyme inhibitors, and Pristiq over other antidepressants.

Payments for food and beverages provided to doctors totaled $224.5 million in 2014, JAMA Internal Medicine editor-at-large Robert Steinbrook, M.D., noted in an accompanying editorial. "If drug and device manufacturers were to stop sending money to physicians for promotional speaking, meals, and other activities without clear medical justification and invest more in independent bona fide research on safety, effectiveness, and affordability, our patients and the health care system would be better off," Steinbrook writes.

Abstract
Full Text
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Gene Tx Approved for Certain Types of B-Cell Lymphoma

Gene Tx Approved for Certain Types of B-Cell ...

First such treatment for certain types of non-Hodgkin lymphoma

Uninsurance Down by One-Third for Cancer Diagnoses in 2014

Uninsurance Down by One-Third for Cancer Diagnoses in ...

Significant decreases in uninsurance seen across all stages and sites assessed in first year of ACA

Diabetes Ups Risk of MACE in Acute Coronary Syndromes

Diabetes Ups Risk of MACE in Acute Coronary ...

Diabetes, but not pre-diabetes, tied to increased risk of major adverse cardiac events in adjusted model

is free, fast, and customized just for you!

Already a member?

Sign In Now »